Abstract: A compound includes an amphiphilic polymer with a hydrophobic block including monomeric units chosen from alkyl (meth)acrylates, alkyl (meth)acrylamides, and combinations thereof; and a hydrophilic cationic block including monomeric units chosen from alkylamino (meth)acrylates, alkylamino (meth)acrylamides, and combinations thereof. The polymer is in the form of a micelle with a central core derived from the hydrophobic block and shell at least partially surrounding the core. The shell includes a plurality of filamentous arms derived from the hydrophilic block and emanating outward from the core. A biological agent is associated with the arms of the micelle.

Abstract: The subject invention provides materials methods for reducing infections in subjects. The materials methods utilize chlorhexidine, which has been found to be surprisingly non-toxic. The lack of toxicity facilitates the use of chlorhexidine in contexts that were not previously thought to be possible.

Abstract: The present invention provides a quinoline derivative for treating triple-negative breast cancer and use thereof in preparing a pharmaceutical composition for treating a tumor.

Abstract: An antimicrobial composition comprising at least two quaternary ammonium compounds selected from: (i) a quaternary ammonium compound having the formula: A4-nSi(R—NHaR1bZ)n and (ii) a quaternary ammonium compound having the formula: NHcR1dZ wherein in each of the at least two quaternary ammonium compounds A, R, R1, a, Z and n are independently selected, and: A is a member selected from the group consisting of alkoxy radicals, alkylether alkoxy radicals, and alkyl radicals; R is a divalent hydrocarbon radical; each R1 is independently a member selected from the group consisting of benzyl, alkyl radicals, alkyl ether hydrocarbon radicals, hydroxyl-containing alkyl radicals, and nitrogen-containing hydrocarbon radicals; Z is a member selected from the group consisting of chloride, bromide, iodide, tosylate, hydroxide, sulfate and phosphate; a is 0, 1 or 2, b is 1, 2 or 3, and the sum of a and b is 3; c is 0, 1, 2 or 3, d is 1, 2, 3 or 4, and the sum of c and d is 4; and n is 1, 2 or 3; and wherein the composition

Abstract: The disclosure relates to methods and compositions to treat an eosinophilic disease or disorder. More particularly, the disclosure provides methods and compositions for treating eosinophilic esophagitis.

Abstract: A deodorant stick comprising: at least about 25% of a liquid triglyceride; at least one antimicrobial; a primary structurant with a melting point of at least about 50° C.; and less than 8% of secondary structurants having a melting point of at least about 60° C.; said stick being free of an aluminum salt; and said stick having a hardness from about 80 mm*10 to about 140 mm*10, as measured by penetration with ASTM D-1321 needle.

Abstract: Provided is a composition for forming a coating film directly on the skin by an electrostatic spray, the composition being capable of forming a coating film having excellent skin compatibility, adhesion, and scratch resistance, having a good feel, and being easy to peel. A composition for forming a coating film, for forming a coating film composed of fibers directly on the skin by an electrostatic spray, the composition comprising the following Components (a), (b), (c), and (d): (a) a polymer having a coating film forming ability (b) one or more volatile substances selected from the group consisting of an alcohol and a ketone (c) a plasticizer (d) a feel modifier other than Component (c).

Abstract: A fluorocarbon emulsion in water for use in fractionated radiotherapy and chemotherapy, wherein said fluorocarbon comprises between 4 and 8 carbon atoms.

Abstract: Compositions of nanolipid carrier molecules comprising PEG molecules and solid and liquid lipids wherein the PEG has a molecular weight of between about 1000 and 5000 are described. Methods of administering nanolipid carrier molecules are also described. Also described is a method for treating fungal ocular infections by topical ocular administration of nanolipid carrier molecules comprising PEG molecules and solid and liquid lipids wherein the PEG has a molecular weight of between about 1000 and 5000.

Abstract: A medical drug devices for transdermal drug delivery systems (TDDS) comprising a novel iontophoretic polymeric microneedle device and its use in administration of drugs.

Abstract: The present invention describes new formulations of semiochemical compounds for mammals in wick diffusers particularly effective in controlling the diffusion of several semiochemicals having different volatilities over long periods of time and independently of the temperature and humidity conditions.

Abstract: The present invention relates to a composition and health functional food for preventing and treating a respiratory inflammation disease using a mixed herbal mixture. Through various experiments, for example, determination of the cell number of BAL (bronchoalveolar lavage) (Experimental Example 1); Determination of CD11b+/Gr-1+ ratio in leukocyte within BAL fluid (Experimental Example 2); Determination of expressed RNA level of inflammatory cytokines in lung tissue (Experimental Example 3); Determination of expressed RNA level of inflammatory cytokines in BALF (Experimental Example 4); Lung histology (Experimental Example 5); Brief Clinical test (Experimental Example 7) etc, it has been verified that the inventive combined extract showed more potent inhibiting effect on respiratory inflammation disease than each herb extract.

Abstract: A biphasic topical product comprising a hydrophilic phase and a lipophilic phase floating on said hydrophilic phase. A method for preparing biphasic topical products.

Abstract: A pharmaceutical active-containing transmucosal delivery device comprises a polymer film comprising a polymer matrix, wherein the film has a pH in the range of about 4 to about 9, and a pharmaceutical active composition disposed on a surface of the polymer film. The composition comprises at least one pharmaceutical active ingredient in the form of particles, and wherein the particles have an average particle size of about 100 nm to about 5 microns, an anti-crystallization agent, and a pH adjusting agent, wherein the concentration of the pharmaceutical active ingredient is at least 20% w/w relative to the total weight of the pharmaceutical active composition. The delivery device exhibits a residence time in the mouth of a subject ranging from about 5 minutes to about 30 minutes and is substantially mucoadhesive to a mucosa surface when placed sublingually under the tongue or placed buccally at the inner lining of the cheek.

Abstract: The invention is concerned with use of oral inorganic pyrophosphate for preventing and/or reducing tissue calcification, particularly soft tissue calcification, and/or diseases or disorders characterized by low plasma PPi levels, as, e.g.

Abstract: Disclosed is a method of treating a fine line or wrinkle in a person's skin, the method comprising topically applying to the fine line or wrinkle a composition comprising an effective amount of Commiphora mukul resin or an extract thereof that includes oleo gum resin, glycerin, water, and hyaluronic acid or a salt form thereof, wherein topical application of the composition to the fine line or wrinkle reduces the appearance of the fine line or wrinkle.

Abstract: A deodorant stick comprising at least 25% by weight liquid triglyceride; a primary antimicrobial having a water solubility of at most about 90 g/L at 25° C.; a fragrance composition comprising at least about 50% natural oils, essential oils, or a combination thereof; and a primary structurant with a melting point of at least 50° C.; said deodorant stick being free of an aluminum salt; and said deodorant stick having a hardness from about 70 mm*10 to about 140 mm*10, as measured by penetration with ASTM D-1321 needle.

Abstract: The present disclosure is directed to a method of preparing a pharmaceutical composition comprising tolerizing immune-modulating particles of polymer-encapsulated gliadin.

Abstract: A composition intended for the remodelling treatment of a scar, by means of topical application, in particular, as a massage adjuvant. The composition takes the form of a microemulsion, preferably with a gel texture, containing a lipophilic compound, a wound healing agent, a humectant and an emulsifying agent, as well as a small amount of water.

Abstract: Cosmetic and dermatological compositions, including color changing compositions, are provided which typically include a plurality of synthetic particles having a size in the micrometer or nanometer range. Each synthetic particle typically includes one or more aggregates of a pigment selected from phenoxazone, phenoxazine, and a derivate or precursor thereof, and a stabilizing material which has a refractive index larger than 1.45; the aggregates having a size larger than about 100 nm and the composition being biodegradable and biocompatible.